Screening Patients With Metastatic Breast Cancer for Psychiatric Disease: a Cross Sectional Study

2021 ◽  
Author(s):  
Raquel Basto ◽  
Cecília Caramujo ◽  
Inês Ferreira Gomes ◽  
Teresa Fraga ◽  
Joana Correia Magalhães ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Psychiatric Disorders ◽  
Palliative Treatment ◽  
Metastatic Breast ◽  
Subscale Score ◽  
Psychiatric Disease ◽  
Cross Sectional ◽  
Ovarian Function Suppression ◽  
Female Patients

Abstract Objective: To evaluate the prevalence of psychiatric disorders in a sample of Portuguese patients with metastatic breast cancer and assess the relationship between these disorders and the characteristics of the oncological disease.Methods: Cross-sectional, single-center study with female patients diagnosed with metastatic breast carcinoma and under palliative treatment between November 2020 and May 2021. Psychiatric disorders were screened by applying and filling-out the MMSE, HADS, BSI, and WHOQoL-Bref instruments at the outpatient daycare unit when patients were present for treatmen. Results: A total of 91 female patients were included, median age 59.79 years. None of the patients had cognitive impairment (MMSE). HADS scale: 18.7% of the patients scored for anxiety and 17.6% for depression. The anxiety subscale score of > 8 (HADS) was related to ovarian function suppression (p<0.001), neoadjuvant therapy (p<0.001), and type of second-line of palliative treatment (p=0.024). The depression subscale score >8 (HADS) was related to the type of surgery performed (p= 0.022), molecular subtype of the tumor (p=0.020), and occurrence of grade 3-4 toxicities in the first (p=0.018), and third-line treatments (p=0.031).Conclusion: The screening of psychiatric disorders through the application of these scales by the medical oncology team may be able to aid in diagnosis and potentially lead to psychiatric referral and intervention at an earlier stage.

scholarly journals Energy System Assessment in Metastatic Breast Cancer: A Cross-Sectional Study

2020 ◽  
Author(s):  
Antonio I Cuesta-Vargas ◽  
Jena Buchan ◽  
Bella Pajares ◽  
Ruiz-Medina Sofía ◽  
Emilio Alba ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Heart Rate ◽  
Metastatic Breast Cancer ◽  
Lower Limb ◽  
Metastatic Breast ◽  
Energy System ◽  
Cross Sectional Study ◽  
Baseline Assessment ◽  
Sectional Study ◽  
Cross Sectional

Abstract Background: Metastasis breast cancer commonly report physical and psychosocial side effects, which requires a supervised exercise prescription with an individualized assessment. This cross-sectional study examined the feasibility of energy system-based assessment, also generating descriptive values for assessment performance in this population.Methods: This cross-sectional study recruited 70 women diagnosed with metastatic breast cancer. After baseline assessment, participants attempted up to three energy system assessments: submaximal aerobic (multi-stage treadmill); anaerobic alactic (30-second sit-to-stand [30-STS]); and anaerobic lactic (adapted burpees). Heart rate and rating of perceived exertion (RPE) were recorded. Secondary outcomes included body composition, CRF and upper- and lower-limb functionality. Results: 64 and 70 of the participants performed the submaximal aerobic test and the 30-STS, respectively, and 5 completed the adapted burpees task. Heart rate and RPE specific to each task were correlated, reflecting increased intensity. Women reported low-moderate levels of CRF [3(2.1)] and moderate-high functionality levels [upper-limb: 65.8% (23.3); lower-limb: 63.7% (34.7)]. Conclusions: Using a combination of heart rate and RPE, as well as baseline assessment of each energy system, clinicians may improve ability to prescribe personalized exercise and give patients greater ability to self-monitor intensity and progress.Trial registration: ClinicalTrials.gov ID NCT03879096

scholarly journals Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report

Cases Journal ◽  
2009 ◽  
Vol 2 (1) ◽  
Author(s):  
Takashi Kawaguchi ◽  
Satoru Iwase ◽  
Hironori Takeuchi ◽  
Ayako Ikeda ◽  
Yujiro Kuroda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Palliative Treatment ◽  
Low Dose ◽  
Metastatic Breast

Observational cross-sectional study to evaluate the prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice. ONCOSUR-AVALOX study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11074-e11074
Author(s):  
Luis Manso ◽  
Ramon Perez-Carrion ◽  
Jose Ignacio Chacon Lopez-Muniz ◽  
Andres Garcia Palomo ◽  
Elena Galve Calvo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Benefit ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
Complete Response ◽  
First Line ◽  
Cross Sectional ◽  
Metastatic Site ◽  
Selection Of

e11074 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites and location of metastases and patient decision on the selection of BEV combined with CT in MBC. Methods: Observational cross-sectional multicenter study in pts with HER2-negative MBC who have received first-line CT with BEV. Results: From November 2010 to November 2011, 124 pts were included: median age 51 (45-64) yr; ECOG: 0=50%; 60% pre-menopausic; 23% triple-negative (TN); 77% hormone receptor-positive (HR+). Metastatic disease: ≥3 sites=42% (TN: 32%; HR+: 45%); location: 44% bone, 35% lung, 30% liver. Most frequent BEV-based combinations were paclitaxel/BEV (53%) and docetaxel/BEV (14.5%); median no. of CT cycles: 6 (5-8). A disease-free survival (DFS) ≥12 months was achieved by 73%; TN: 68%; HR+: 76%. Overall response rate (ORR) was 58%: 51% partial response (PR), 7% complete response (CR); 28% stable disease (SD) and 10% disease progression. TN: ORR 44% (40% PR), clinical benefit 80% (36% SD); HR+: ORR 62% (54% PR), clinical benefit 87% (25% SD). 58% presented at least one toxicity, mainly grade 1-2; 26% BEV-related: only 3 (2.4%) grade 3 toxicities; no grade 4. Receiving adjuvant hormonal therapy was associated to DFS ≥12 months (p<0.05). ER+ tumors (OR: 0.215; 95% CI: 0.08-0.56; p=0.002) and one metastatic site, vs. ≥3 sites (OR: 0.309; 95% CI: 0.12-0.83; p=0,020) were independent factors associated with the selection of paclitaxel-BEV therapy in the overall population (TN or HR+). Metastases in the liver were significantly related to paclitaxel-BEV administration (p<0.01). Conclusions: Our findings suggest that first-line CT with BEV is an active and tolerable treatment option for pts with TN and HR+ MBC. ER+ tumors and a single metastatic site were identified as independent factors for the selection of a paclitaxel-BEV therapy. The presence of metastases in the liver was significantly associated to the administration of a paclitaxel-BEV regimen.

Prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice: Oncosur-Avalox—Observational cross-sectional study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12020-e12020
Author(s):  
Luis Manso ◽  
Andres Garcia-Palomo ◽  
Ramon Perez-Carrion ◽  
Jose Ignacio Chacon ◽  
Xabier Mielgo Rubio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Liver Metastases ◽  
Clinical Benefit ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
First Line ◽  
Cross Sectional ◽  
Patient Decision ◽  
Selection Of

e12020 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites, location of metastases and patient decision on the selection of BEV combined with CT in MBC. Methods: Observational cross-sectional multicenter study in patients with HER2- negative MBC who have received first-line CT with BEV. Results: 219 patients were included: median age 51(44-63) yr; ECOG: 0=53%; 60.4% pre-menopausic; 23.9% triple-negative (TN);76.2 % hormone receptor positive (HR+).Metastatic disease: ≥3 sites=39.2% (TN: 22%; HR+: 43.9%); location: 45.2% bone, 37.4% liver, 30.1% lung. Most frequent BEV combinations were paclitaxel/BEV(60.7%) and docetaxel/BEV(12.8%); median no. of CT cycles: 6 (5- 8). A disease-free survival (DFS) ≥12 months was achieved by 82.8%; TN: 78.9%; HR+: 83.3%. Overall response rate (ORR) was 62.7%: 53.6% partial response (PR), 9.1% complete response (CR); 25.4% stable disease (SD) and 7.2% disease progression (4.8% non evaluated). TN:ORR 54.2% (47.9% PR), clinical benefit 80% (27.1% SD); HR+:ORR 65.8% (55.7% PR), clinical benefit 89.9% (24.1% SD). 66.2% presented at least one toxicity, mainly grade 1-2; 32% BEV-related: only 3 grade 3 toxicities; no grade 4. Receiving adjuvant hormonal therapy was associated to DFS ≥12 months (p<0.05). ER+ tumors (OR:0.326;95%CI:0.16-0.65;p=0.002) and patient decision after consider doctor opinion (OR:0.026;95%CI:0.01-0.74; p=0.085) were independent factors associated with the selection of paclitaxel-BEV in the overall population (TN or HR+). Liver metastases were significantly related to paclitaxel-BEV administration (p<0.01). Conclusions: First-line CT with BEV is an effective and safe scheme for patients with TN and HR+ MBC. ER+ tumors and patient decision after consider doctor opinion were identified as independent factors for the selection of paclitaxel-BEV therapy. The presence of liver metastases was significantly associated to the administration of a paclitaxel-BEV regimen.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with metastatic breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12569-e12569
Author(s):  
Xiaoxiang Guan ◽  
Hong Zhu ◽  
Wenzhuan Xie ◽  
Jing Zhao ◽  
Guoqiang Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Circulating Tumor Dna ◽  
Internal Tissue ◽  
Genomic Alterations ◽  
Invasive Approach ◽  
Hybrid Capture ◽  
Female Patients ◽  
Tumor Dna

e12569 Background: Breast cancer is the most common malignancy among women worldwide. It is particularly important to provide precise therapies based on genomic alterations, especially for metastatic breast cancers (MBC), which exhibit a high tumor heterogeneity and dynamic changes during the course of disease progression. However, genomic sampling upon metastatic tissue biopsy frequently encountered difficulties due to its inherent invasive approach such as insufficient samples and clinical risks. Our study aims to assess the genomic alternation landscape of metastatic breast cancer detected by blood-based circulating tumor DNA (ctDNA) and evaluate the assay performance. Methods: We performed hybrid capture-based next-generation sequencing (NGS) of 150 genes on ctDNA from 203 female patients with MBC. The mean sequencing depth was more than 3000×. The results were compared with our internal tissue genomic database (297 female patients with MBC) tested by NGS and TCGA database (N=982) tested by whole exome sequencing. Genomic alterations including single nucleotide variation (SNV), insertions/deletions, copy number variations, gene rearrangement and fusions were assessed. Results: Genomic data from 203 female patients with metastatic breast cancer were analyzed via ctDNA [median age 53 years (range, 46–61 years)]. Evidence of ctDNA as estimated by the maximum somatic allele frequency (MSAF) was detected in 95.6% of the patients (median=7.1 alterations/patient), and 97.0% of the patients had at least one characterized altered gene. The most frequently mutated genes identified for SNV occurred in TP53 (47.8%), PIK3CA (36.0%), and ESR1 (16.3%) upon ctDNA analysis and TP53 (73.2%), PIK3CA (38.4%), and ESR1 (4.0%) from our internal tissue database. However, in TCGA cohort, where most patients were presented with early stage diseases, the most mutated gene in terms of SNV was PIK3CA (32.5%), followed by TP53 (30.7%) and TTN (16.0%). The status of ERBB2 amplifications had a high concordance among ctDNA (14.8%), tissue (14.9%), and TCGA database (13.5%). The MSAF level was significantly higher for the fusion-present cases (P=0.048) or amplification cases (p<0.0001) than non-fusion or non-amplification cases. Conclusions: Our study has suggested that ctDNA profiling is a feasible approach for the molecular analysis in metastatic breast cancer and may better capture the mutational landscape of MBC for further clinical implications.

Sign in / Sign up

Export Citation Format

Share Document